Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28186224 | 0.98 | DRD2 (0.48) | DRD2DRD4DRD3ALDH1A1KMT2A | |
| SCHEMBL3423574 | 0.87 | BCHE (0.57) | — | |
| SCHEMBL19125641 | 0.86 | DRD2 (0.56) | DRD2DRD4DRD3ALDH1A1KMT2A | |
| SCHEMBL2592594 | 0.86 | DRD2 (0.56) | DRD2DRD4DRD3ALDH1A1KMT2A | |
| SCHEMBL29238442 | 0.83 | KMT2A (0.58) | KMT2A | |
| SCHEMBL14690575 | 0.83 | KMT2A (0.58) | KMT2A | |
| SCHEMBL13586009 | 0.80 | ATM (0.44) | DRD2DRD4DRD3 | |
| SCHEMBL23531478 | 0.79 | KMT2A (0.70) | ALDH1A1KMT2A | |
| SCHEMBL28130536 | 0.79 | KMT2A (0.70) | ALDH1A1KMT2A | |
| SCHEMBL18541807 | 0.79 | KMT2A (0.70) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977106-A | 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives | PIERRE FABRE MEDICAMENT (FR) | 1999-11-02 | — | — | US | claimed |
| EP-0794949-B1 | NOVEL 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS DRUGS | PF MEDICAMENT (FR) | 1998-07-29 | — | — | EP | claimed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| US-5977106-A | 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives | PIERRE FABRE MEDICAMENT (FR) | 1999-11-02 | — | — | US | disclosed |
| WO-1999020622-A1 | 3-OXO-2(H)-1,2,4-TRIAZINE DERIVATIVES AS LIGANDS OF 5HT1A RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 1999-04-29 | — | — | WO | disclosed |
| CN-1205700-A | Indolylalkyl derivatives of benzodioxan methylamines as 5-HTiA receptor ligands | AMERICAN HOME PROD (US) | 1999-01-20 | — | — | CN | disclosed |
| EP-0861248-A1 | INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5750724-A | SEROTONIN 5-HT REUPTAKE INHIBITORS; ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5750724-A | SEROTONIN 5-HT REUPTAKE INHIBITORS; ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997017343-A1 | INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5245051-A | Antipsychotic chroman derivatives of benzodioxanmethylamine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
| US-5235055-A | Antipsychotic quinoline derivatives of benzodioxanmethylamine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | DRD2 1901/4885DRD4 792/4885DRD3 1355/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | DRD2 1901/4885DRD4 792/4885DRD3 1355/4885 |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | DRD2 4/4885DRD4 7/4885DRD3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.